-
Je něco špatně v tomto záznamu ?
Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats
B. Bądzyńska, I. Vaneckova, J. Sadowski, S. Hojná, E. Kompanowska-Jezierska
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- antagonisté endotelinového receptoru A farmakologie terapeutické užití MeSH
- antagonisté endotelinového receptoru B farmakologie terapeutické užití MeSH
- antihypertenziva farmakologie terapeutické užití MeSH
- atrasentan farmakologie terapeutické užití MeSH
- eliminace ledvinami účinky léků MeSH
- endotelin-1 farmakologie terapeutické užití MeSH
- hemodynamika účinky léků MeSH
- hypertenze farmakoterapie metabolismus MeSH
- krevní tlak účinky léků MeSH
- ledviny účinky léků metabolismus MeSH
- modely nemocí na zvířatech MeSH
- oligopeptidy farmakologie terapeutické užití MeSH
- oxid dusnatý metabolismus MeSH
- piperidiny farmakologie terapeutické užití MeSH
- potkani inbrední SHR MeSH
- potkani Sprague-Dawley MeSH
- receptor endotelinu A účinky léků MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Endothelin 1 (ET-1) seems essential in salt-dependent hypertension, and activation of ETA receptors causes renal vasoconstriction. However, the response in the renal medulla and the role of tissue NO availability has never been adequately explored in vivo. We examined effects of ETA and ETB receptor blockade (atrasentan and BQ788) on blood pressure (MAP), medullary blood flow (MBF) and medullary tissue NO. Effects of systemic and intramedullary blocker application were compared in anesthetized normotensive ET-1-pretreated Sprague-Dawley rats (S-D), in salt-dependent hypertension (HS/UNX) and in spontaneously hypertensive rats (SHR). Total renal blood flow (RBF) was measured using a Transonic renal artery probe, MBF as laser-Doppler flux, and tissue NO signal using selective electrodes. In normotensive rats ET-1 significantly increased MAP, decreased RBF (-20%) and renal medullary NO. In HS/UNX rats atrasentan decreased MAP and increased medullary NO, earlier and more profoundly with intravenous infusion. In SHR atrasentan decreased MAP, more effectively with intravenous infusion; the increase in tissue NO (∼10%) was similar with both routes; however, only intramedullary atrasentan increased MBF. No consistent responses to BQ788 were seen. We confirmed dominant role of ETA receptors in regulation of blood pressure and renal hemodynamics in normotensive and hypertensive rats and provided novel evidence for the role of ETA in control of intrarenal NO bioavailability in salt-dependent and spontaneous hypertension. Under conditions of activation of the endothelin system ETB stimulation preserved medullary perfusion.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011945
- 003
- CZ-PrNML
- 005
- 20220530150443.0
- 007
- ta
- 008
- 220425s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejphar.2021.174445 $2 doi
- 035 __
- $a (PubMed)34492284
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Bądzyńska, Bożena $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, A. Pawińskiego 5, 02-106, Warsaw, Poland. Electronic address: bbadzynska@imdik.pan.pl
- 245 10
- $a Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats / $c B. Bądzyńska, I. Vaneckova, J. Sadowski, S. Hojná, E. Kompanowska-Jezierska
- 520 9_
- $a Endothelin 1 (ET-1) seems essential in salt-dependent hypertension, and activation of ETA receptors causes renal vasoconstriction. However, the response in the renal medulla and the role of tissue NO availability has never been adequately explored in vivo. We examined effects of ETA and ETB receptor blockade (atrasentan and BQ788) on blood pressure (MAP), medullary blood flow (MBF) and medullary tissue NO. Effects of systemic and intramedullary blocker application were compared in anesthetized normotensive ET-1-pretreated Sprague-Dawley rats (S-D), in salt-dependent hypertension (HS/UNX) and in spontaneously hypertensive rats (SHR). Total renal blood flow (RBF) was measured using a Transonic renal artery probe, MBF as laser-Doppler flux, and tissue NO signal using selective electrodes. In normotensive rats ET-1 significantly increased MAP, decreased RBF (-20%) and renal medullary NO. In HS/UNX rats atrasentan decreased MAP and increased medullary NO, earlier and more profoundly with intravenous infusion. In SHR atrasentan decreased MAP, more effectively with intravenous infusion; the increase in tissue NO (∼10%) was similar with both routes; however, only intramedullary atrasentan increased MBF. No consistent responses to BQ788 were seen. We confirmed dominant role of ETA receptors in regulation of blood pressure and renal hemodynamics in normotensive and hypertensive rats and provided novel evidence for the role of ETA in control of intrarenal NO bioavailability in salt-dependent and spontaneous hypertension. Under conditions of activation of the endothelin system ETB stimulation preserved medullary perfusion.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antihypertenziva $x farmakologie $x terapeutické užití $7 D000959
- 650 _2
- $a atrasentan $x farmakologie $x terapeutické užití $7 D000077868
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a antagonisté endotelinového receptoru A $x farmakologie $x terapeutické užití $7 D065130
- 650 _2
- $a antagonisté endotelinového receptoru B $x farmakologie $x terapeutické užití $7 D065131
- 650 _2
- $a endotelin-1 $x farmakologie $x terapeutické užití $7 D019332
- 650 _2
- $a hemodynamika $x účinky léků $7 D006439
- 650 _2
- $a hypertenze $x farmakoterapie $x metabolismus $7 D006973
- 650 _2
- $a ledviny $x účinky léků $x metabolismus $7 D007668
- 650 _2
- $a oxid dusnatý $x metabolismus $7 D009569
- 650 _2
- $a oligopeptidy $x farmakologie $x terapeutické užití $7 D009842
- 650 _2
- $a piperidiny $x farmakologie $x terapeutické užití $7 D010880
- 650 _2
- $a potkani inbrední SHR $7 D011918
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a receptor endotelinu A $x účinky léků $7 D044022
- 650 _2
- $a eliminace ledvinami $x účinky léků $7 D065667
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vaneckova, Ivana $u Laboratory of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Czech Republic. Electronic address: ivana.vaneckova@fgu.cas.cz
- 700 1_
- $a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, A. Pawińskiego 5, 02-106, Warsaw, Poland. Electronic address: jsadowski@imdik.pan.pl
- 700 1_
- $a Hojná, Silvie $u Laboratory of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Czech Republic. Electronic address: Silvie.Hojna@fgu.cas.cz
- 700 1_
- $a Kompanowska-Jezierska, Elżbieta, $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, A. Pawińskiego 5, 02-106, Warsaw, Poland. Electronic address: ekompanowska@imdik.pan.pl $d 1959- $7 xx0273376
- 773 0_
- $w MED00001641 $t European journal of pharmacology $x 1879-0712 $g Roč. 910, č. - (2021), s. 174445
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34492284 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220530150441 $b ABA008
- 999 __
- $a ok $b bmc $g 1789505 $s 1163146
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 910 $c - $d 174445 $e 20210904 $i 1879-0712 $m European journal of pharmacology $n Eur J Pharmacol $x MED00001641
- LZP __
- $a Pubmed-20220425